Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CureVac N-V stock | $55.11

Learn how to easily invest in CureVac N-V stock.

CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in CureVac N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CVAC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CureVac N-V stock price (NASDAQ: CVAC)

Use our graph to track the performance of CVAC stocks over time.

CureVac N-V shares at a glance

Information last updated 2021-09-11.
Latest market close$55.11
52-week range$43.00 - $151.80
50-day moving average $63.29
200-day moving average $84.10
Wall St. target price$72.64
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.16

Buy CureVac N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CureVac N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CureVac N-V price performance over time

Historical closes compared with the close of $55.11 from 2021-09-16

1 week (2021-09-10) -18.33%
1 month (2021-08-18) -16.54%
3 months (2021-06-18) -11.03%
6 months (2021-03-18) -38.44%
1 year (2020-09-18) 5.80%
2 years (2019-09-14) N/A
3 years (2018-09-14) N/A
5 years (2016-09-14) N/A

CureVac N-V financials

Revenue TTM $48.9 million
Gross profit TTM $34.7 million
Return on assets TTM -10.17%
Return on equity TTM -38.63%
Profit margin -264.21%
Book value $3.94
Market capitalisation $12.6 billion

TTM: trailing 12 months

Shorting CureVac N-V shares

There are currently 4.5 million CureVac N-V shares held short by investors – that's known as CureVac N-V's "short interest". This figure is 12.4% up from 4.0 million last month.

There are a few different ways that this level of interest in shorting CureVac N-V shares can be evaluated.

CureVac N-V's "short interest ratio" (SIR)

CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V shares currently shorted divided by the average quantity of CureVac N-V shares traded daily (recently around 728954.6474359). CureVac N-V's SIR currently stands at 6.24. In other words for every 100,000 CureVac N-V shares traded daily on the market, roughly 6240 shares are currently held short.

However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V shares, or, against the total number of tradable CureVac N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CureVac N-V shares in existence, roughly 20 shares are currently held short) or 0.0565% of the tradable shares (for every 100,000 tradable CureVac N-V shares, roughly 57 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CureVac N-V.

Find out more about how you can short CureVac N-V stock.

CureVac N-V share dividends

We're not expecting CureVac N-V to pay a dividend over the next 12 months.

CureVac N-V overview

CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Frequently asked questions

What percentage of CureVac N-V is owned by insiders or institutions?
Currently 51.298% of CureVac N-V shares are held by insiders and 23.459% by institutions.
How many people work for CureVac N-V?
Latest data suggests 455 work at CureVac N-V.
When does the fiscal year end for CureVac N-V?
CureVac N-V's fiscal year ends in December.
Where is CureVac N-V based?
CureVac N-V's address is: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076
What is CureVac N-V's ISIN number?
CureVac N-V's international securities identification number is: NL0015436031

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site